S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

Y-mAbs Therapeutics News Headlines (NASDAQ:YMAB)

$30.10
+0.16 (+0.53 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$29.52
Now: $30.10
$32.30
50-Day Range
$29.89
MA: $33.05
$35.80
52-Week Range
$19.03
Now: $30.10
$36.29
Volume100,731 shs
Average Volume169,864 shs
Market Capitalization$1.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.13

Headlines

Y-mAbs Therapeutics (NASDAQ YMAB) News Headlines

Source:
DateHeadline
Y-mAbs Announces Positive Pre-BLA Meeting with FDA for OmburtamabY-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab
finance.yahoo.com - February 26 at 5:41 PM
Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Sees Significant Decline in Short InterestY-mAbs Therapeutics, Inc (NASDAQ:YMAB) Sees Significant Decline in Short Interest
www.americanbankingnews.com - February 14 at 2:38 AM
Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Chairman Sells $132,120.00 in StockY-mAbs Therapeutics, Inc (NASDAQ:YMAB) Chairman Sells $132,120.00 in Stock
www.americanbankingnews.com - February 11 at 7:22 PM
Zacks: Analysts Expect Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) to Announce -$0.67 EPSZacks: Analysts Expect Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) to Announce -$0.67 EPS
www.americanbankingnews.com - February 10 at 10:52 AM
Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Receives Consensus Rating of "Buy" from BrokeragesY-mAbs Therapeutics, Inc (NASDAQ:YMAB) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 6 at 3:46 AM
Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare ConferenceY-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 5:26 PM
Is Y-mAbs Therapeutics, Inc. (YMAB) A Good Stock To Buy?Is Y-mAbs Therapeutics, Inc. (YMAB) A Good Stock To Buy?
finance.yahoo.com - December 16 at 5:31 PM
Y-mAbs Therapeutics neuroblastoma vaccine nabs accelerated review status in U.S.Y-mAbs Therapeutics' neuroblastoma vaccine nabs accelerated review status in U.S.
seekingalpha.com - December 12 at 2:00 PM
Y-mAbs’ GD2-GD3 Vaccine Granted Rare Pediatric Disease DesignationY-mAbs’ GD2-GD3 Vaccine Granted Rare Pediatric Disease Designation
finance.yahoo.com - December 12 at 2:00 PM
Y-mAbs Announces Positive Naxitamab Frontline DataY-mAbs Announces Positive Naxitamab Frontline Data
finance.yahoo.com - December 11 at 5:45 PM
Y-mAbs Announces Positive Naxitamab Frontline Data Y-mAbs Announces Positive Naxitamab Frontline Data 
finance.yahoo.com - December 11 at 12:43 PM
Y-mAbs and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for OmburtamabY-mAbs and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for Omburtamab
finance.yahoo.com - December 5 at 7:10 PM
Y-mAbs to Host R&D Event and Live Webcast on Wednesday, December 11Y-mAbs to Host R&D Event and Live Webcast on Wednesday, December 11
finance.yahoo.com - December 5 at 2:10 PM
Y-mAbs Initiates Rolling Submission of Biologics License Application to U.S. FDA for Naxitamab for Treatment of NeuroblastomaY-mAbs Initiates Rolling Submission of Biologics License Application to U.S. FDA for Naxitamab for Treatment of Neuroblastoma
finance.yahoo.com - November 29 at 1:06 PM
Y-mAbs omburtamab shows positive effect in rare abdominal cancerY-mAbs' omburtamab shows positive effect in rare abdominal cancer
seekingalpha.com - November 15 at 2:53 PM
Y-mAbs Announces Update on Omburtamab in DSRCTY-mAbs Announces Update on Omburtamab in DSRCT
finance.yahoo.com - November 15 at 9:53 AM
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2019 Results - Earnings Call TranscriptY-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2019 Results - Earnings Call Transcript
seekingalpha.com - November 15 at 12:13 AM
Y-mAbs Therapeutics, Inc. Common Stock (YMAB) Earnings Report DateY-mAbs Therapeutics, Inc. Common Stock (YMAB) Earnings Report Date
www.nasdaq.com - November 13 at 10:17 PM
Y-mAbs Announces Third Quarter 2019 Financial Results and Recent Corporate DevelopmentsY-mAbs Announces Third Quarter 2019 Financial Results and Recent Corporate Developments
finance.yahoo.com - November 13 at 5:16 PM
Y-mAbs to Announce Third Quarter 2019 Financial and Operating Results on November 13Y-mAbs to Announce Third Quarter 2019 Financial and Operating Results on November 13
finance.yahoo.com - November 6 at 7:57 PM
Monday 11/4 Insider Buying Report: TRN, YMABMonday 11/4 Insider Buying Report: TRN, YMAB
www.nasdaq.com - November 4 at 12:55 PM
Y-mAbs Flags Potential Delay In Pre-BLA Meeting, Sticks To Regulatory Filing TimelineY-mAbs Flags Potential Delay In Pre-BLA Meeting, Sticks To Regulatory Filing Timeline
www.msn.com - November 3 at 8:59 AM
BRIEF-Y-mAbs Therapeutics Says It Received E-Mail Notification From FDA On Oct. 31BRIEF-Y-mAbs Therapeutics Says It Received E-Mail Notification From FDA On Oct. 31
www.msn.com - November 2 at 12:03 AM
Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional SharesY-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
www.marketwatch.com - November 1 at 7:01 PM
Y-mAbs Therapeutics reports delay in U.S. application for omburtamabY-mAbs Therapeutics reports delay in U.S. application for omburtamab
seekingalpha.com - November 1 at 2:00 PM
Y-mAbs prices equity offeringY-mAbs prices equity offering
seekingalpha.com - October 30 at 6:33 AM
Y-mAbs Announces Pricing of Public Offering of Common StockY-mAbs Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 29 at 10:36 PM
Y-mAbs Announces Proposed Public Offering of Common StockY-mAbs Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 29 at 5:35 PM
Y-mAbs up 6% on positive omburtamab dataY-mAbs up 6% on positive omburtamab data
seekingalpha.com - October 28 at 2:22 PM
Were Not Very Worried About Y-mAbs Therapeuticss (NASDAQ:YMAB) Cash Burn RateWe're Not Very Worried About Y-mAbs Therapeutics's (NASDAQ:YMAB) Cash Burn Rate
finance.yahoo.com - October 28 at 2:22 PM
We're Not Very Worried About Y-mAbs Therapeutics's (NASDAQ:YMAB) Cash Burn RateWe're Not Very Worried About Y-mAbs Therapeutics's (NASDAQ:YMAB) Cash Burn Rate
finance.yahoo.com - October 28 at 2:22 PM
Y-mAbs Announces Positive Omburtamab Clinical DataY-mAbs Announces Positive Omburtamab Clinical Data
finance.yahoo.com - October 28 at 9:21 AM
Y-mAbs Announces Naxitamab UpdateY-mAbs Announces Naxitamab Update
finance.yahoo.com - October 25 at 12:22 PM
Y-mAbs inks new research agreement with Memorial Sloan KetteringY-mAbs inks new research agreement with Memorial Sloan Kettering
seekingalpha.com - September 19 at 6:42 PM
Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility GrowsWedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows
www.benzinga.com - September 4 at 3:52 PM
Y-mAbs Announces Data to be Presented at 2019 CTOSY-mAbs Announces Data to be Presented at 2019 CTOS
finance.yahoo.com - August 30 at 11:37 AM
Y-mAbs Therapeutics (YMAB) CEO Claus Moller on Q2 2019 Results - Earnings Call TranscriptY-mAbs Therapeutics' (YMAB) CEO Claus Moller on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 15 at 10:40 AM
YmAbs Therapeutics, Inc. (YMAB) Q2 2019 Earnings Call TranscriptYmAbs Therapeutics, Inc. (YMAB) Q2 2019 Earnings Call Transcript
finance.yahoo.com - August 15 at 10:40 AM
Y-mAbs Therapeutics EPS misses by $0.04Y-mAbs Therapeutics EPS misses by $0.04
seekingalpha.com - August 14 at 8:51 PM
Y-mAbs Announces Second Quarter 2019 Financial Results and Recent Corporate DevelopmentsY-mAbs Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
finance.yahoo.com - August 14 at 8:51 PM
How Much Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Do Insiders Own?How Much Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Do Insiders Own?
finance.yahoo.com - August 8 at 3:57 PM
Y-mAbs to Announce Second Quarter 2019 Financial and Operating Results on August 14Y-mAbs to Announce Second Quarter 2019 Financial and Operating Results on August 14
finance.yahoo.com - August 7 at 6:30 PM
Y-mAbs to start naxitamab application in November for neuroblastomaY-mAbs to start naxitamab application in November for neuroblastoma
seekingalpha.com - July 8 at 3:44 PM
Y-mAbs Announces Successful Pre-BLA Meeting with FDA for NaxitamabY-mAbs Announces Successful Pre-BLA Meeting with FDA for Naxitamab
finance.yahoo.com - July 8 at 11:21 AM
Y-mAbs updates on top candidates omburtamab and nixitamabY-mAbs updates on top candidates omburtamab and nixitamab
seekingalpha.com - July 1 at 3:39 PM
Y-mAbs Secures Commercial Radiolabeling CapacityY-mAbs Secures Commercial Radiolabeling Capacity
finance.yahoo.com - July 1 at 11:30 AM
Y-mAbs Announces Recruitment Status for Pivotal TrialsY-mAbs Announces Recruitment Status for Pivotal Trials
finance.yahoo.com - July 1 at 11:30 AM
Y-mAbs Announces Data to be Presented at 2019 ASCO Annual MeetingY-mAbs Announces Data to be Presented at 2019 ASCO Annual Meeting
finance.yahoo.com - May 15 at 8:47 PM
Y-mAbs Announces First Quarter 2019 Financial Results and Recent Corporate DevelopmentsY-mAbs Announces First Quarter 2019 Financial Results and Recent Corporate Developments
finance.yahoo.com - May 11 at 11:43 AM
Y-mAbs Therapeutics To Present at the Bank of America Merrill Lynch Healthcare Conference in Las VegasY-mAbs Therapeutics To Present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas
finance.yahoo.com - May 8 at 12:18 PM
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel